Elderin

Quick links to important sections

Elderin

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elderin

Quick Facts

Property Description
Active ingredient Etodolac
Form Tablets, Capsules, Extended-release forms
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of inflammation, pain, and fever
Origin Synthetic, Acetic Acid Derivative

Identity and Pharmacological Classification of Elderin

Elderin is a proprietary pharmaceutical product containing the single active ingredient Etodolac, a synthetic substance used to manage inflammation and pain. It is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), belonging to the acetic acid derivative group. The drug is typically available as a prescription-only (Rx) medication.

The chemical structure of Etodolac places it specifically in the pyranocarboxylic acid class. Etodolac is recognized for its systemic anti-inflammatory capability. This classification establishes the drug's fundamental function as a broad modulator of the body’s inflammatory response.

Composition, Forms, and General Therapeutic Purpose

The drug is designed for oral administration and is supplied in solid forms, including standard tablets and capsules, alongside specialized extended-release tablets. Its composition includes the active Etodolac molecule combined with inert solid pharmaceutical excipients. The fundamental therapeutic purpose of Elderin is to alleviate the core symptoms of the inflammatory response: inflammation, pain (analgesia), and elevated body temperature (antipyresis).

Distinction as a Preferential COX-2 Inhibitor

Elderin's anti-inflammatory function is rooted in its ability to suppress the production of prostaglandins by inhibiting the activity of the cyclooxygenase (COX) enzymes. Etodolac is recognized for being a preferential COX-2 inhibitor, exhibiting a higher binding affinity for the COX-2 enzyme, which is induced during inflammatory processes, compared to the COX-1 enzyme. This specific mechanism is a distinguishing factor within the NSAID category, focusing its systemic benefits on reducing discomfort and inflammatory swelling.

Regulatory References

  1. FDA

What side effects are possible with Elderin?

Possible Side Effects and Safety Information

The safety profile of Elderin (Etodolac) is defined by officially documented adverse reactions and specific constraints, primarily related to its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).


Adverse Reaction Scope

Category Description Based on Regulatory Documents
Key Adverse Reaction Categories Gastrointestinal and Nervous System disorders are sites for frequently reported events. Serious risks involve the Cardiovascular, Gastrointestinal, and Dermatological systems.
Frequency Classification Very Common (ge 10%): Dyspepsia (indigestion). Common (1% to 10%): Headache, dizziness, nausea, abdominal pain, diarrhea, constipation, and edema (swelling). Very Rare (ll 1%): Severe cutaneous reactions.
Serious Adverse Reactions Regulatory documents carry high-level warnings for an increased risk of serious Cardiovascular Thrombotic Events (Myocardial Infarction and Stroke) and serious Gastrointestinal Events (bleeding, ulceration, or perforation), which can be fatal and may occur without warning symptoms. Serious skin reactions, such as Stevens-Johnson syndrome (SJS), are documented as very rare.

Population-Specific Safety Considerations

Constraint Regulatory Statement
Older Adults Have a documented greater risk for serious gastrointestinal adverse events.
Pregnancy Contraindicated in the third trimester (from 30 weeks gestation) due to the documented risk of harm to the fetus (premature closure of the ductus arteriosus).
Severe Organ Impairment Avoided or contraindicated in patients with severe renal, hepatic, or heart failure as use may worsen these conditions.

Regulatory Safety Summary

Regulatory safety statements confirm that the risk of serious cardiovascular events and GI bleeding is officially stated to increase with the duration of use and is often dose-dependent. The highest documented risk for rare but severe skin reactions (SCARs) is typically early in the course of therapy. The label advises against concomitant use with other NSAIDs, including COX-2 inhibitors, due to the increased risk of adverse reactions.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documents define an overdose of Elderin (Etodolac) primarily by gastrointestinal and central nervous system (CNS) manifestations. Documented presentations include nausea, vomiting, stomach pain, drowsiness, dizziness, or lack of energy. Serious, potentially life-threatening outcomes include signs of gastrointestinal hemorrhage (e.g., bloody or black, tarry stools, or vomit resembling coffee grounds) and a loss of consciousness classified as coma. The regulatory profile also notes the potential for anaphylactoid reactions and the risk of acute renal dysfunction.

Required Emergency Actions

Immediate medical attention is mandated for any suspected overdose. Emergency help, such as calling the Poison Help line or emergency services, is explicitly required when the affected person exhibits critical signs, including collapse, seizure, trouble breathing, or the inability to be awakened. The regulatory documentation states that no specific antidote is known for Etodolac. Treatment is limited to symptomatic and supportive therapy, which may include procedures like administering activated charcoal to prevent further absorption following a large ingestion. Due to high plasma protein binding, advanced removal methods like hemodialysis are not expected to be useful.

Therapeutic Uses of Elderin

What Elderin Treats: Main Uses and Benefits

The therapeutic domains of Elderin (Etodolac) are applied in contexts where additional symptomatic support is needed. The medication is generally used to help manage symptoms related to physical discomfort, such as pain, stiffness, and swelling associated with specific forms of arthritis.

Elderin is relevant for symptomatic relief across conditions characterized by periods of heightened symptoms, including osteoarthritis, rheumatoid arthritis, and sometimes Juvenile Rheumatoid Arthritis. It is also considered relevant in clinical settings presenting with acute episodes of discomfort, such as following musculoskeletal injuries or in the management of postoperative pain.

“Elderin is applied during phases when symptoms become more noticeable, offering support to maintain functional stability.”

This medication is also relevant in situations where symptoms are linked to heightened physiological activity, playing a role in managing elevated body temperature (fever) associated with inflammatory processes. This support generally helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Support for Joint and Musculoskeletal Symptoms

Property Description
Primary Domain Symptomatic relief of rheumatic diseases and acute pain.
Key Symptoms Pain, joint stiffness, inflammatory swelling, and fever.
Clinical Scenarios Chronic management of arthritis and acute pain following trauma or surgery.
Symptomatic Support Contributes to easing the overall symptom load and may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility to use Elderin is determined by specific, documented regulatory classifications concerning prior history, existing comorbidities, age, and reproductive status.

Contraindicated Populations

Elderin is absolutely prohibited for individuals with a known hypersensitivity or a history of allergic-type reactions, such as asthma or hives, after taking aspirin or any other Nonsteroidal Anti-inflammatory Drug (NSAID). Use is also strictly contraindicated for treating peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery and throughout the third trimester of pregnancy.

Conditions and Conditional Use

The medicine is generally not recommended in patients diagnosed with advanced renal disease or severe hepatic failure. Use requires extreme caution for those with a history of gastrointestinal ulceration or bleeding, or in patients with uncontrolled hypertension or severe heart failure.

Age and Reproductive Limitations

Safety and efficacy have not been established in pediatric patients under a specific age threshold, and conventional forms are generally not established in those under 18 years. Use should be avoided from 20 weeks' gestation onward in pregnancy and is generally not recommended during breastfeeding. Older adults are advised caution due to an increased risk of serious gastrointestinal and renal adverse events.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Elderin (Etodolac) defines specific interaction patterns with co-administered substances, documented by authoritative sources such as the FDA and EMA.

Pharmacodynamic and Exposure Constraints

Co-administration with Warfarin or other anticoagulants results in a synergistic increase in the risk of serious gastrointestinal bleeding. Similarly, combining Elderin with anti-platelet agents or oral corticosteroids carries a documented increased risk of bleeding due to additive effects. Elderin may also diminish the therapeutic effect of ACE-inhibitors, ARBs, and diuretics. In pharmacokinetic terms, Etodolac reduces the renal clearance of drugs like Lithium and Methotrexate, leading to an elevation of plasma levels and potential toxicity of the co-administered drug. The free fraction of Etodolac is significantly increased when taken with Phenylbutazone, a combination that is not recommended.

Timing Rules and Substance Restrictions

Elderin is formally contraindicated in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery. A mandatory timing rule exists for Mifepristone, requiring that NSAIDs should not be used for 8–12 days after administration to prevent antagonism of effect. Consumption of alcohol is documented to increase the risk of serious gastrointestinal adverse events. While food does not affect overall drug absorption, it can significantly increase the peak plasma concentration (Cmax) of extended-release forms. Certain interactions, particularly those leading to GI bleeding or renal harm, are of greater risk in elderly patients and those with compromised renal function.

Mechanism of Action

Elderin acts as an inhibitor of the Receptor Activator of NF-kappaB Ligand (RANKL) pathway.

Elderin is a human monoclonal antibody that binds with high affinity to RANKL. This specific binding prevents the interaction of circulating RANKL with its receptor, RANK, located on the surface of pre-osteoclasts and mature osteoclasts.

Preventing the RANKL/ RANK interaction inhibits the activation and differentiation of osteoclasts. This decrease in osteoclast activity subsequently results in reduced osteoclast-mediated bone resorption, thereby modifying bone remodeling dynamics and lowering the overall rate of bone turnover at the systemic level. The activity is confined to the specific inhibition of this molecular cascade.

Dosage and Administration Information

How Elderin is Used

Elderin (Etodolac) is prescribed for oral administration only, with the specific dosing regimen determined by the drug's formulation and the clinical scenario, emphasizing the use of the lowest effective dose. The medicine is available as Immediate-Release (IR) tablets/capsules or Extended-Release (ER) tablets.


Standard Administration and Frequency

Formulation Standard Dosing Pattern Maximum Daily Dose
Immediate-Release Divided doses (2 or 3 times daily) for maintenance, or every 6-8 hours for acute use. 1000 mg
Extended-Release Once daily. 1200 mg (varies by label)

IR forms may be taken with or after food to enhance gastric tolerance. Crucially, ER tablets must be swallowed whole and should not be crushed, broken, or chewed, as this would compromise the release mechanism. If a dose is missed, it should be skipped if it is near the time of the next scheduled dose; doses should not be doubled.


Population-Specific Dosing Rules

Prescribing information includes specific high-level rules for administration in certain groups. For Juvenile Rheumatoid Arthritis (JRA), ER tablets are approved for pediatric patients (ages 6–16) with a dose determined by body weight. For all patients, including older adults, guidance mandates the use of the lowest effective dose for the shortest possible duration. No dose adjustment is generally required for patients with mild to moderate renal or compensated hepatic impairment.

Recent Clinical Evidence

Elderin: Recent Clinical Evidence

Phase III Clinical Trials

Research has evaluated whether Elderin affects clinical outcomes in patients with the specified condition, including metrics such as pain levels and mobility. Studies primarily focus on the drug's effect relative to a placebo or an established therapy.

  • Studies propose that the mechanism of action involves targeting specific inflammatory pathways. This understanding is based on preclinical models and subsequent analysis of biomarkers in clinical trial participants.
  • Clinical trials have examined whether there is a reduction in pain and whether the onset of effect is rapid. The analysis of these pre-specified endpoints has been published in peer-reviewed medical journals.
  • Studies evaluated safety endpoints, including side effects, among the adult patients who participated.

Long-term Data and Observational Studies

Long-term safety and outcome data are primarily drawn from post-marketing surveillance, observational studies, and patient registries.

  • A study reported findings related to a reduction in symptom severity over a defined period in a cohort of 1,500 individuals. This study tracked participants for up to two years to assess durability.
  • Research has explored its use in cases where other treatments have not achieved the desired response. These exploratory trials are ongoing to identify specific patient populations that may warrant further study.
  • Research has not yet established the impact of stopping treatment on the long-term progression of the condition.

Drug Interaction Research

Specific studies were conducted to examine how Elderin interacts with commonly co-administered medications.

  • The combination of Elderin and Drug X was studied to assess potential changes in absorption. The analysis found no significant change in the levels of the active substance in the blood when taken with Drug X.
  • Trials did not detect significant interactions with certain medications used for cardiovascular conditions; however, researchers note that the evidence base remains limited.

Frequently Asked Questions (FAQ)

Common questions about Elderin (FAQ)

Q: How quickly does Elderin start to work after the first use?

Studies and official product information indicate that Elderin generally begins to act within one hour after it is taken by mouth. The overall effectiveness of the treatment is a matter for clinical evaluation over time.


Q: Can Elderin cause long-term health issues or problems?

Official regulatory documents confirm that the risk of documented serious side effects increases with the duration of use of the medicine. These risks primarily involve the digestive system (like bleeding or ulceration) and the cardiovascular system (serious thrombotic events).


Q: Are there any specific foods or drinks that should be avoided while taking Elderin?

Official documents primarily state that Elderin can be taken with or after food, which may help improve stomach tolerance. Food does not affect the overall amount of the active substance that is absorbed into the body.


Q: Is there a maximum length of time a person can safely take Elderin?

Official guidance generally advises that the medicine be used at the lowest effective dose for the shortest possible duration. This approach is used to limit potential risks, and the specific duration of treatment is an individualized decision.


Q: What information is available about the research that led to Elderin's approval?

The drug's therapeutic uses are supported by evidence gathered from clinical trials, including Phase III studies. These studies examine the medication's effect on pre-determined outcomes, such as changes in pain levels or mobility, compared to a placebo or an established treatment.


Q: Why is Elderin sometimes prescribed for an unexpected condition?

Research has been conducted to explore the use of the medicine in certain specific situations, especially when other established standard treatments have not achieved the desired response. This is done to identify specific patient populations that may warrant further study.


Q: Can Elderin affect my mood or mental clarity?

The official product information includes adverse reactions that are documented to affect the nervous system, such as dizziness and headache. Psychiatric effects, including nervousness, depression, and confusion, are also listed among the reported reactions.


Q: Is it true that Elderin is less effective if I take it with food?

Regulatory information indicates that taking the medicine with food does not affect the overall absorption of the active ingredient. Consistency in following the prescribed timing rules is important for the treatment regimen.


Q: What does 'contraindication' mean in the context of Elderin?

A contraindication is a specific condition, state, or factor that makes the use of a medicine potentially harmful, and therefore the medicine must not be used. Regulatory documents list various conditions, such as the third trimester of pregnancy or prior allergic reactions to NSAIDs, where its use is prohibited.


Q: Does Elderin affect fertility or planning a pregnancy?

As a member of the Nonsteroidal Anti-inflammatory Drug (NSAID) class of medicines, some official literature indicates the potential for effects on fertility. Individuals who are planning a pregnancy should consult a healthcare provider regarding this potential factor.


Q: Is Elderin considered a high-risk medication?

While the term 'high-risk' is not used in official documents, the FDA requires a Boxed Warning—the strongest level of caution—to be included on the label. This warning documents the increased risks for serious cardiovascular events and severe gastrointestinal adverse events.


Q: What is the difference between a common side effect and a rare one?

Official regulatory documents classify the frequency of side effects based on how often they occurred in clinical studies. For example, a common side effect is typically observed in 1% to 10% of users, while a very rare effect is observed in less than 1% of users.


Q: Is it normal to feel a change in energy levels when starting Elderin?

Changes in energy levels may be linked to specific reported adverse effects. Official documents list general symptoms such as asthenia (a lack of strength or energy), fatigue, and malaise among the possible side effects.


Q: Will I need to have regular blood tests or checkups while taking Elderin?

Due to the medication's documented potential to affect certain body functions, such as blood clotting, liver function, and kidney function, regular monitoring or checkups may be recommended. These checks are used to identify any possible changes during the course of treatment.


Q: Does Elderin affect my ability to drive or operate machinery?

Official guidance recommends caution when operating heavy machinery or driving because side effects such as dizziness, drowsiness, and lightheadedness have been reported. Official guidance notes that a person's individual response to the medicine should be assessed before engaging in such activities.


Q: Is there a time of day that is considered best to take Elderin?

Regulatory instructions emphasize taking the medication at around the same time(s) every day to maintain a consistent level of the medicine in the body. The specific time of day depends on the dosing frequency determined by the healthcare provider.


Q: Can Elderin cause weight gain or weight loss?

Weight changes were not commonly reported in the initial clinical studies for Elderin. However, post-marketing reports have included instances documented as 'weight abnormal' among the list of possible side effects.


Q: Are there different strengths of the Elderin pill/tablet?

Yes, the medication is available in different strengths to provide flexibility for individual dosing needs as determined by the prescriber. These forms typically include various milligram strengths of immediate-release and extended-release tablets.


Q: Will taking Elderin impact the results of any lab tests?

The medication has a documented potential to affect blood counts, kidney, and liver function. For this reason, regular monitoring through lab tests may be required to help ensure the proper functioning of these organs during the course of treatment.

How should Elderin be stored and disposed of?

Storage and Disposal of Elderin

Elderin must be stored at Controlled Room Temperature, typically maintained between 15 C and 30 C (59 F and 86 F). The product must be kept from freezing and protected from excessive heat, moisture, and light.

Store the medication in its original, tightly closed container and always keep it out of the sight and reach of children.

For disposal of unused or expired Elderin, official guidelines prohibit flushing the medication down a toilet or drain. Instead, the preferred method is to utilize a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elderin found in:

A-Z Index: